IMUGENE LIMITED — Director's Dealing 2024

Jan 31, 2024

Appendix 3Y Change of Director's Interest Notice

Rule 3.19A.2

Appendix 3Y

Change of Director's Interest Notice

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX becomes ASX's property and may be made public.

Introduced 30/09/01 Amended 01/01/11

Name of entity	Imugene Limited
ABN	99 009 179 551

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

Name of director	Paul Hopper
Date of last notice	19 January 2024

Part 1 - Change of director's relevant interests in securities

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

Direct or indirect interest	Direct and Indirect
Nature of indirect interest(including registered holder)	Director related Parties
Date of change	01 February 2024
No. of securities held prior to change	(1) Direct Shares - 2,894,314 ORDINARY FULLYPAID SHARES(2) Indirect Shares - 317,154,000 ORDINARYFULLY PAID SHARES(3) 2,900,000 - ESOP OPTIONS(4) 2,916,666 - LISTED OPTIONS @ $0.118,expiring 31 August 2026(5) 3,901,500 - PERFORMANCE RIGHTS AWARD
Class	(1) Direct Shares - ORDINARY FULLY PAIDSHARES(2) Indirect Shares - ORDINARY FULLY PAIDSHARES
Number acquired	(1) 1,381,422 - ORDINARY FULLY PAID SHARES(Subject to voluntary escrow 12m after issue date)(2) 110,790,024 - ORDINARY FULLY PAIDSHARES (Subject to voluntary escrow 12m afterissue date)
Number disposed	(2) 10,000,000 ORDINARY FULLY PAID
Value/Consideration	(1) $0.0155 PER ORDINARY FULLY PAID SHARE(2) $0.0155 PER ORDINARY FULLY PAID SHARE

• See chapter 19 for defined terms. 01/01/2011 Appendix 3Y Page 1

Appendix 3Y Change of Director's Interest Notice

	Appendix 3YChange of Director's Interest Notice
No. of securities held after change	(1) Direct Shares - 4,275,736 ORDINARY FULLYPAID SHARES (1,381,422 Shares - Subject tovoluntary escrow 12m after issue date)(2) Indirect Shares - 417,944,024 ORDINARYFULLY PAID SHARES (110,790,024 Shares -Subject to voluntary escrow 12m after issue date)(3) 2,900,000 - ESOP OPTIONS(4) 2,916,666 - LISTED OPTIONS @ $0.118,expiring 31 August 2026(5) 3,901,500 - PERFORMANCE RIGHTS AWARD
Nature of change	Shares acquired: (1) and (2) Shares issued torelated and unrelated party vendors of Vaxinia PtyLtd pursuant to Resolutions 1 and 2 as approved byshareholders at the Extraordinary General Meetingof the Company held on 18 November 2019.Shares disposed: (2) Transfer of shares for nilconsideration.

Part 2 - Change of director's relevant interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of "notifiable interest of a director" should be disclosed in this part.

Detail of contract	N/A
Nature of interest	N/A
Name of registered holder(if issued securities)	N/A
Date of change	N/A
No. and class of securitiesto which interest relatedprior to change	N/A
Interest acquired	N/A
Interest disposed	N/A
Value/Consideration	N/A
Interest after change	N/A

Part 3 -[+] Closed period

Were the interests in the securities orcontracts detailed above traded during a+closed period where prior written clearancewas required?	NO
If so, was prior written clearance provided toallow the trade to proceed during this period?	N/A
If prior written clearance was provided, onwhat date was this provided?	N/A

• See chapter 19 for defined terms. 01/01/2011 Appendix 3Y Page 2